

1 **Risk factors for long-term consequences of COVID-19 in hospitalised**
2 **adults in Moscow using the ISARIC Global follow-up protocol:**
3 **StopCOVID cohort study**

4 Daniel Munblit^{1,2,3*}, Polina Bobkova^{1*}, Ekaterina Spiridonova^{1*}, Anastasia Shikhaleva^{1*},
5 Aysylu Gamirova^{1*}, Oleg Blyuss^{1,4*}, Nikita Nekliudov¹, Polina Bugaeva¹, Margarita
6 Andreeva¹, Audrey DunnGalvin^{1,5}, Pasquale Comberiat⁶, Christian Apfelbacher⁷, Jon
7 Genuneit⁸, Sergey Avdeev⁹, Valentina Kapustina¹⁰, Alla Guekht³, Victor Fomin¹¹, Andrey A
8 Svistunov¹¹, Peter Timashev¹², Thomas M Drake¹³, Sarah Wulf Hanson¹⁴, Laura Merson¹⁵,
9 Peter Horby¹⁵, Louise Sigfrid¹⁵, Janet T Scott¹⁶, Malcolm G Semple^{17,18}, John O Warner², Theo
10 Vos¹⁴, Piero Olliaro¹⁵, Petr Glybochko¹¹, Denis Butnaru¹¹ and Sechenov StopCOVID Research
11 Team

- 12 1. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health,
13 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
14 2. Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of
15 Medicine, Imperial College London, London, United Kingdom
16 3. Research and Clinical Center for Neuropsychiatry, Moscow, Russia
17 4. School of Physics, Astronomy and Mathematics, University of Hertfordshire, College Lane,
18 Hatfield, United Kingdom
19 5. School of Applied Psychology, University College Cork, Cork City, Ireland
20 6. Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa,
21 Italy
22 7. Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke
23 University Magdeburg, Magdeburg, Germany
24 8. Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig,
25 Germany
26 9. Clinic of Pulmonology, Sechenov First Moscow State Medical University (Sechenov University),
27 Moscow, Russia
28 10. Department of Internal Medicine №1, Institute of Clinical Medicine, Sechenov First Moscow State
29 Medical University (Sechenov University), Moscow, Russia
30 11. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
31 12. Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov
32 University), Moscow, Russia
33 13. Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK
34 14. Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
35 15. ISARIC Global Support Centre, Nuffield Department of Medicine, University of Oxford, Oxford,
36 UK
37 16. MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
38 17. Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection,
39 Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool,
40 Liverpool, UK
41 18. Department of Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK
42
43

44 *Authors contributed equally to the paper.
45
46

47

48

49

Corresponding author:

50

Daniel Munblit, MD, PhD. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia and Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom

54

Email: daniel.munblito8@imperial.ac.uk

55

56

57

Sechenov StopCOVID Research Team (Group authors)

58

Elina Abdeeva¹, Nikol Alekseeva¹, Elena Antsiferova¹, Elena Artigas¹, Anastasiia Bairashevskaya¹, Anna Belkina¹, Vadim Bezrukov¹, Semyon Bordyugov¹, Maria Bratukhina¹, Salima Deunezhewa¹, Khalisa Elifkhanova¹, Anastasia Ezhova¹, Yulia Filippova¹, Aleksandra Frolova¹, Julia Ganieva¹, Anastasia Gorina¹, Yulia Kalan¹, Bogdan Kirillov¹, Mariia Korgunova¹, Alexandra Krupina¹, Anna Kuznetsova¹, Ekaterina Listovskaia¹, Margarita Mikheeva¹, Aigun Mursalova¹, Marina Ogandzhanova¹, Mikhail Rumyantsev¹, Denis Smirnov¹, Nataliya Shishkina¹, Yasmin El-Taravi¹, Maria Varaksina¹, Maria Vodianova¹, Anna Zezyulina¹

66

67

1. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

68

69

The names of the authors are in alphabetic order

70

71

72 ABSTRACT

73 **Background** The long-term sequelae of COVID-19 remain poorly characterised. In this
74 study, we aimed to assess long-standing symptoms (LS) (symptoms lasting from the time of
75 discharge) in previously hospitalised patients with COVID-19 and assess associated risk
76 factors.

77 **Methods** This is a longitudinal cohort study of adults (≥ 18 years of age) with clinically
78 diagnosed or laboratory-confirmed COVID-19 admitted to Sechenov University Hospital
79 Network in Moscow, Russia. Data were collected from patients discharged between April 8
80 and July 10, 2020. Participants were interviewed via telephone using Tier 1 ISARIC Long-
81 term Follow-up Study CRF and the WHO CRF for Post COVID conditions. Reported
82 symptoms were further categorised based on the system(s) involved. Additional information
83 on dyspnoea, quality of life and fatigue was collected using validated instruments.
84 Multivariable logistic regressions were performed to investigate risk factors for development
85 of LS categories.

86 **Findings** Overall, 2,649 of 4,755 patients discharged from the hospitals were available for
87 the follow-up and included in the study. The median age of the patients was 56 years (IQR,
88 46–66) and 1,353 (51.1%) were women. The median follow-up time since hospital discharge
89 was 217.5 (200.4–235.5) days. At the time of the follow-up interview 1247 (47.1%)
90 participants reported LS. Fatigue (21.2%, 551/2599), shortness of breath (14.5%, 378/2614)
91 and forgetfulness (9.1%, 237/2597) were the most common LS reported. Chronic fatigue
92 (25%, 658/2593) and respiratory (17.2% 451/2616) were the most common LS categories.
93 with reporting of multi-system involvement (MSI) less common (11.3%; 299). Female sex
94 was associated with LS categories of chronic fatigue with an odds ratio of 1.67 (95%
95 confidence interval 1.39 to 2.02), neurological (2.03, 1.60 to 2.58), mood and behaviour
96 (1.83, 1.41 to 2.40), dermatological (3.26, 2.36 to 4.57), gastrointestinal (2.50, 1.64 to 3.89),
97 sensory (1.73, 2.06 to 2.89) and respiratory (1.31, 1.06 to 1.62). Pre-existing asthma was
98 associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02,
99 1.24 to 3.18) and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to
100 2.32).

101 **Interpretation** 6 to 8 months after acute infection episode almost a half of patients
102 experience symptoms lasting since hospital discharge. One in ten individuals experiences
103 MSI. Female sex is the main risk factor for majority of the LS categories. chronic pulmonary
104 disease is associated with a higher risk of chronic fatigue development, and asthma with
105 neurological and mood and behaviour changes. Individuals with LS and MSI should be the
106 main target for future research and intervention strategies.

107 **Funding** This study is supported by Russian Fund for Basic Research and UK Embassy in
108 Moscow. The ISARIC work is supported by grants from: the NIHR Health Protection
109 Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in
110 partnership with Public Health England (PHE), in collaboration with Liverpool School of
111 Tropical Medicine and the University of Oxford [award 200907], Wellcome Trust and
112 Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates
113 Foundation [OPP1209135], EU Platform for European Preparedness Against (Re-) emerging
114 Epidemics (PREPARE) [FP7 project 602525] This research was funded in part, by the
115 Wellcome Trust. The views expressed are those of the authors and not necessarily those of
116 the DID, NIHR, Wellcome Trust or PHE.

117

118 **Word count:**

119

Research in context

Evidence before this study

Evidence suggests that COVID-19 may result in short- and long-term consequences to health. Most studies do not provide definitive answers due to a combination of short follow-up (2-3 months), small sample size, and use of non-standardised tools. There is a need to study the longer-term health consequences of previously hospitalised patients with COVID-19 infection and to identify risk factors for sequelae.

Added value of this study

To our knowledge, this is the largest cohort study (n=2,649) with the longest follow-up since hospital discharge (6-8 months) of previously hospitalised adult patients. We found that 6-8 months after discharge from the hospital, around a half (47.1%) of patients reported at least one long-standing symptom since discharge. Once categories of symptoms were assessed, chronic fatigue and respiratory problems were the most frequent clusters of long-standing symptoms in our patients. Of those patients having long-term symptoms, a smaller proportion (11.3%) had multisystem involvement, with three or more categories of long-standing symptoms present. Although most patients developed symptoms since discharge, a smaller number of individuals experienced symptom beginning weeks or months after the acute phase. Female sex was a predictor for most of the symptom categories at the time of the follow-up interview, with chronic pulmonary disease associated with chronic fatigue-related symptoms, and asthma with a higher risk of neurological symptoms, mood and behaviour problems.

Implications of all the available evidence

The majority of patients experienced long-lasting symptoms 6 to 8 months after hospital discharge and almost half reported at least one long-standing symptom, with chronic fatigue and respiratory problems being the most frequent. A smaller number reported multisystem impacts with three or more long-standing categories present at follow-up. A higher risk was found for women, for chronic pulmonary disease with chronic fatigue, and neurological symptoms and mood and behaviour problems with asthma. Patterns of the symptom development following COVID-19 should be further investigated in future research.

120

121 INTRODUCTION

122 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed
123 a significant burden on health services and society world-wide. There have now been well
124 over 100 million coronavirus disease 2019 (COVID-19) cases reported with a mortality rate
125 of around 2.2% globally¹. The acute presentation of COVID-19 has now been well
126 investigated, with fever, cough, shortness of breath and anosmia among the most commonly
127 reported symptoms²⁻⁴.

128

129 It has become evident that a substantial proportion of people experience ongoing symptoms
130 including fatigue and muscle weakness, joint and muscle pain, and breathlessness, months
131 after the acute phase of COVID-19⁵⁻⁷. This phenomenon is now commonly referred to as
132 Long COVID but has also been described as post-COVID syndrome, the post-COVID-19
133 condition⁸ or patients have been labelled COVID long-haulers^{9,10}. The recently published UK
134 National Institute for Health and Clinical Excellence (NICE) COVID-19 guideline defines the
135 syndrome as “signs and symptoms that develop during or after an infection consistent with
136 COVID-19, continue for more than 12 weeks and are not explained by an alternative
137 diagnosis”¹¹. However, publications have used a range of definitions based on limited
138 evidence from small, heterogeneous cohorts⁷. Overall, there is still a paucity of long-term
139 follow-up data, which means we have limited knowledge of the full range of symptoms,
140 duration of disease and potential risk factors. Recently published data from China describing
141 long-term consequences of COVID-19 show that 76% of previously hospitalised adult
142 patients have at least one symptom 6 months after acute infection⁶.

143

144 There is an urgent need for accurate long-term follow-up of COVID-19 patients⁷, to inform
145 future management plans and address the devastating impacts of this condition on the
146 quality of life (QoL) of people affected. This observational cohort study aimed to investigate
147 the incidence of long-term consequences in adults previously hospitalised for COVID-19 and
148 to assess risk factors for Long COVID in Moscow, Russia. We used the standardised follow-
149 up data collection protocol of the International Severe Acute Respiratory and Emerging
150 Infection Consortium (ISARIC).

151

152 METHODS

153 Study design, setting and participants

154 This is a longitudinal cohort study of patients with suspected or confirmed COVID-19
155 infection admitted to four Sechenov University Hospital Network in Moscow, Russia. We

156 collected the follow-up data between December 2, 2020 and January 14, 2021 from patients
157 discharged between April 8, 2020 and July 10, 2020. We included adult patients (≥ 18 years
158 of age), with both reverse transcriptase polymerase chain reaction (RT-PCR) confirmed
159 SARS-CoV-2 infection, corresponding to U07.1 as per International Classification of Diseases
160 (ICD), and clinically confirmed infection, encoded as U07.2 when the laboratory testing
161 result is negative, inconclusive or unavailable.

162

163 The acute phase data were extracted from electronic medical records (EMR) and the Local
164 Health Information System (HIS) at the host institution using the modified and translated
165 ISARIC WHO Clinical Characterisation protocol (CCP)¹². Details of the acute phase data
166 collection are described elsewhere³. The acute-phase dataset included demographics,
167 symptoms, comorbidities, chest computer tomography (CT) reports, supportive care data,
168 and clinical outcomes at discharge. The study was approved by the Sechenov University
169 Local Ethics Committee on April 22, 2020 (protocol number 08–20). A protocol amendment
170 enabling serial follow-up of the cohort was approved on November 13, 2020.

171

172 Information about the current condition and persisting symptoms was collected by
173 telephone using the Tier 1 ISARIC Long-term Follow-up Study case report form (CRF)
174 developed by the ISARIC Global COVID-19 follow up working group, with adaptations,
175 translated into Russian assessing the patients' physical and mental health⁹. Additional
176 information was added from the WHO CRF for Post COVID conditions¹³. The follow-up CRF
177 documented data on demographics, lifestyle and socioeconomic data, history of vaccination,
178 hospital stay and readmissions, mortality (after the initial index event), presence of newly
179 developed symptoms at the time of follow-up interview and symptom duration (1-2 weeks; >
180 2-4 weeks; >1-2 months; >2-3 months; >3-6 months; from the time of discharge), dyspnoea,
181 fatigue, quality of life (QoL) and difficulties in functioning before the COVID-19 illness and
182 at the time of the follow-up (**Supplementary material**).

183

184 The participants were asked to report on dyspnoea, QoL and difficulties in functioning before
185 the COVID-19 illness (retrospectively) and presently (at the time they were completing the
186 questionnaire), to enable comparative assessment of the respective variables. We used the
187 British Medical Research Council (MRC) dyspnoea scale, the EuroQoL five-dimension five-
188 level (EQ-5D-5L) questionnaire, the EuroQoL Visual Analogue Scale (EQ-VAS) asking
189 participants to score their QoL from 0 (worst imaginable health) to 100 (best imaginable
190 health), UNICEF/Washington disability score and World Health Organisation Disability
191 Assessment Schedule (WHODAS 2.0). The study was registered with EuroQoL as part of the
192 ISARIC collaborative effort (EuroQoL ID 37035).

193

194 Data collection and entry were performed by a team of medical students who signed
195 confidentiality agreements, underwent training in basic data entry into REDCap and
196 telephone interviews. Students have already had extensive data extraction experience gained
197 from the previous research³ and were supervised by senior academic staff members.

198

199 The research team members attempted to contact patients three times before declaring them
200 lost to follow up. If available by telephone, the patients were asked to provide their verbal
201 consent to the interview. The patient's record ID was cross-checked with existing
202 demographic data to ensure reliable collation of the follow-up surveys with the existing
203 acute-phase data extracted previously.

204

205 **Data management**

206 We used REDCap electronic data capture tools (Vanderbilt University, Nashville, TN, USA)
207 hosted at Sechenov University and Microsoft Excel (Microsoft Corp, Redmond, WA, USA) for
208 data collection, storage and management^{11,12}. The baseline characteristics, including
209 demographics, symptoms on admission and comorbidities had been extracted from EMRs
210 and entered into REDCap previously.

211 **Definitions**

212 The acute disease severity was stratified in accordance with Arnold et al.¹⁰ by a three-
213 category scale based on the degree of required supportive care during hospital stay: mild (no
214 supplementary oxygen or intensive care), moderate (supplementary oxygen during
215 hospitalisation) and severe (need for non-invasive respiratory modalities (NIV), invasive
216 mechanical ventilation (IMV) and/or admission to intensive care unit (ICU)). A difference of
217 10 points at EQ-VAS defined relevant change in the health status⁴.

218

219 For the purpose of this study, we defined “long-standing symptoms” (LS) as symptoms
220 present since hospital discharge. LS present at the time of follow-up were also categorised
221 into respiratory, gastrointestinal, dermatological, chronic fatigue, neurological, mood and
222 behaviour, sensory (**Table S1**). Symptom categorisation was based on previously published
223 literature^{14,15} and international expert group discussions.

224 **Outcomes**

225 The primary outcomes included the prevalence of LS and prevalence of categories of LS at
226 follow-up.

227

228 The secondary outcomes included any symptom prevalence at follow-up (regardless of their
229 duration), and health status assessed by EuroQoL VAS, fatigue scale, and MRC dyspnea
230 scale.

231 **Statistical analysis**

232 Descriptive statistics were calculated for baseline characteristics. Continuous variables were
233 summarised as median (with interquartile range) and categorical variables as frequency
234 (percentage). The chi-squared test or Fisher's exact test was used for testing differences in
235 proportions between groups. The Wilcoxon rank-sum test was used for testing the
236 hypotheses about differences in means between the groups.

237

238 We performed multivariable logistic regression to investigate associations of demographic
239 characteristics, comorbidities, and severity of acute phase COVID-19 with LS categories
240 presence at the time of the follow-up interview. To enhance the robustness of the effect
241 estimates, only comorbidities that were present in at least 3% of the cohort were included in
242 the modelling. Primary analysis was performed using the full dataset, whereas sensitivity
243 analysis included only a subset of people with RT-PCR confirmed SARS-CoV-2 infection
244 (ICD U07.1). We have previously found no significant differences in clinical signs, symptoms,
245 laboratory test results and risk factors for in-hospital mortality between clinically diagnosed
246 patients and patients with positive RT-PCR ³. Therefore, primary analysis was performed
247 using the full cohort. Robustness of findings was then investigated via sensitivity analysis
248 which included only a subset with confirmed SARS-CoV-2 infection. We have not performed
249 any imputation for missing data.

250

251 Venn diagrams were used to present the coexistence of the five most common long-standing
252 symptoms.

253

254 Two-sided p-values were reported for all statistical tests, a p-value below 0.05 was
255 considered to be statistically significant. Statistical analysis was performed using R version
256 3.5.1.


257

258 **Role of the funding source**

259 The funder of the study had no role in study design, data collection, data analysis, data
260 interpretation, or writing of the report. All authors had full access to all the data in the study
261 and had final responsibility for the decision to submit for publication.

262 RESULTS

263 As outlined in **Figure 1**, out of 5,040 patients hospitalised with suspected COVID-19 to the
264 hospitals before July 10, 2020, 4,755 were discharged alive or transferred to another facility.
265 Out of 4,019 patients with accurate contact information available, 2,649 were available for
266 follow-up (response rate 68.5%), 2,649 of whom had no missing baseline data in the
267 electronic database and were included in the analysis. Of the 3,868 patients with contact
268 information available 52 (1.3%) died after the hospital discharge.



269
270 **Figure 1.** Flow diagram of patients with COVID-19 admitted to Sechenov University Hospital
271 Network between April 8 and July 10, 2020. PCR, polymerase chain reaction.

272
273 Out of 2,649 participants, 1,358 patients (51.3%) had RT-PCR-confirmed SARS-CoV-2
274 infection, whereas 1291 (48.7%) were clinically diagnosed with COVID-19. In-hospital case
275 fatality ratio was 167/2674 (6.2%) in laboratory-confirmed and 118/2360 (5%) in clinically
276 diagnosed patients (p=0.09). The median age was 56 years (IQR, 46–66; range, 18–100

277 years), 1,353 (51.1%) were women. Median follow-up time post-discharge was 217.5 days
278 (IQR 200.4-235.5, range 18-100). 1,948 participants (77.4%) had a higher education; 1,531,
279 (59.8%) of the participants were working part- or full-time and 830 (32.4%) were retired
280 (**Table 1**).

281

282 The most common pre-existing comorbidity on admission was hypertension (1,219, 46.2%),
283 followed by obesity (514, 19.6%) and type II diabetes (369, 14.1%). Most of the patients had
284 mild COVID-19 (1,637, 63.2%), with 902 (34%) classified as moderate and 68 (2.6%) as
285 severe, respectively.

286

287 At the time of the follow-up interview, 1115 (42.1%) of the participants reported no
288 symptoms, 444 (16.8%) reported one, 313 (11.8%) two and 777 (29.3%) three or more
289 symptoms, with fatigue, shortness of breath, and forgetfulness being the most common. Just
290 under half (1247;47.1%) reported one or more LS. Persistent fatigue 551/2599 (21.2%),
291 breathlessness 378/2614 (14.5%), forgetfulness 237/2597 (9.1%), muscle weakness 199/2592
292 (7.7%), problems seeing 198/2598 (7.6%), hair loss 183/2580 (7.1%), and problems sleeping
293 180/2583 (7%) were the most common LS reported at follow-up. Detailed information on all
294 the symptoms, including duration, is presented in **Table S2**.

295


296 Although many patients had LS since discharge, some participants reported at least one
297 symptom of a differing duration during follow-up interview; 285 (10.8%) had experienced
298 these symptoms for 3 to 6 months, 179 (6.8%) between 2 and 3 months, 157 (5.9%) between 1
299 and 2 months, 103 (3.9%) between 2 and 4 weeks and 140 (5.3%) between 1 and 2 weeks,
300 respectively. The duration of the ten common symptoms at the time of the follow-up is
301 shown in **Figure 2**.

302


		Total	Laboratory-confirmed RT-PCR "+" (n=1358)	Clinically diagnosed RT-PCR "-" (n=1291)
Age (median, IQR)		56 (46-66)	57 (47-67)	55 (44-65)
Age groups (years)	<50	870 (32.8%)	407 (30%)	463 (35.9%)
	50-69	1294 (48.8%)	673 (49.6%)	621 (48.1%)
	70-79	304 (11.5%)	169 (12.4%)	135 (10.5%)
	≥80	181 (6.8%)	109 (8%)	72 (5.6%)
Sex	Female	1353 (51.1%)	683 (50.3%)	670 (51.9%)
Time from admission to discharge, days	Median (IQR)	14.6 (12-17.6)	15.1 (12.8-18.7)	13.7 (11.6-16.1)
Time since discharge, days	Median (IQR)	217.5 (200.4-235.5)	215.3 (195.5-234.5)	220.5 (204.4-237.3)
Highest completed educational level	School	240 (9.5%)	125 (9.7%)	115 (9.3%)
	University	1948 (77.4%)	989 (76.8%)	959 (78%)
	Not completed formal education or training	37 (1.5%)	13 (1%)	24 (2%)
Occupation/ Working status				
Occupation/working status before Covid-19	Working full-time	1473 (57.5%)	745 (54.9%)	728 (56.4%)
	Working part-time	58 (2.3%)	25 (1.8%)	33 (2.6%)
	Full time carer (children or others)	47 (1.8%)	22 (1.6%)	25 (1.9%)
	Unemployed	47 (1.8%)	23 (1.7%)	24 (1.9%)
	Unable to work due to chronic illness	5 (0.2%)	2 (0.1%)	3 (0.2%)
	Student	21 (0.8%)	8 (0.6%)	13 (1%)
	Retired/ Early retirement due to illness	871 (34.0%)	459 (33.8%)	412 (31.9%)
	Do not want to answer	155 (6.1%)	82 (6%)	73 (5.7%)
Comorbidities				
Chronic cardiac disease (not hypertension)		476 (18.1%)	273 (20.3%)	203 (15.8%)
Hypertension		1219 (46.2%)	646 (47.8%)	573 (44.4%)
Revascularization of peripheral and/or coronary arteries		98 (3.7%)	68 (5.1%)	30 (2.3%)
Chronic pulmonary disease (not asthma)		193 (7.3%)	110 (8.2%)	83 (6.5%)
Asthma (physician diagnosed)		121 (4.6%)	73 (5.4%)	48 (3.7%)
Chronic kidney disease		123 (4.7%)	72 (5.4%)	51 (4%)

Obesity (as defined by clinical staff)		514 (19.6%)	263 (19.6%)	251 (19.6%)
Moderate or severe liver disease		19 (0.7%)	11 (0.8%)	8 (0.6%)
Mild liver disease		50 (1.9%)	24 (1.8%)	26 (2%)
Asplenia		8 (0.3%)	4 (0.3%)	4 (0.3%)
Chronic neurological disorder		121 (4.6%)	78 (5.8%)	43 (3.4%)
Malignant neoplasm		93 (3.5%)	62 (4.6%)	31 (2.4%)
Chronic hematologic disease		30 (1.1%)	21 (1.6%)	9 (0.7%)
AIDS / HIV	on ART	4 (0.2%)	0 (0%)	4 (0.3%)
	not on ART	5 (0.2%)	3 (0.2%)	2 (0.2%)
Diabetes Mellitus	Type 1	13 (0.5%)	6 (0.4%)	7 (0.5%)
	Type 2	369 (14.1%)	198 (14.7%)	171 (13.4%)
Rheumatologic disorder		96 (3.7%)	43 (3.2%)	53 (4.1%)
Dementia		25 (1%)	18 (1.3%)	7 (0.5%)
Tuberculosis		2 (0.1%)	1 (0.1%)	1 (0.1%)
Malnutrition		6 (0.2%)	2 (0.1%)	4 (0.3%)
With no comorbidities		908 (34.3%)	452 (33.3%)	456 (35.3%)
With 1 comorbidity		723 (27.3%)	341 (25.1%)	382 (29.6%)
With 2 comorbidities		512 (19.3%)	267 (19.7%)	245 (19%)
With 3+ comorbidities		506 (19.1%)	298 (21.9)	208 (16.1%)
COVID-19 Severity				
	Mild (not requiring supplementary oxygen or ventilation)	1679 (63.4%)	841 (61.9%)	838 (64.9%)
	Moderate (requiring only supplementary oxygen)	902 (34%)	479 (35.3%)	423 (32.8%)
	Severe (requiring non-invasive ventilation, or invasive ventilation or intensive care admission)	68 (2.6%)	38 (2.8%)	30 (2.3%)

Table 1. Demographic characteristics of patients admitted to the Sechenov University Hospital Network. Data are n (%), n/N (%), or median (IQR). Statistically significant results (p<0.05) are highlighted in bold.



303



304

305

306

307

Figure 2. Stacked bar charts presenting (a) prevalence and (b) duration of ten most common symptoms reported at the time of the follow-up interview. The full data is shown in the Table S2.

308 A degree of overlap was found between the five most common LS, with 79/900 (8.8%) of
309 patients experiencing both persistent fatigue and breathlessness, 54 (6%) persistent fatigue
310 and muscle weakness. A smaller proportion of patients reported a combination of persistent
311 fatigue, breathlessness and muscle weakness - 26/900 (2.9%) with 16 (1.8%) patients having
312 all five (**Figure S1**).

313

314 With regard to categories of LS, chronic fatigue was found to be the most common 658/2593
315 (25%) at the time of the follow-up interview, followed by respiratory 451/2616 (17.2%),
316 neurological 375/2586 (14.5%), mood and behaviour changes 284/2591 (11%) and
317 dermatological 206/2583 (8%) symptoms. A smaller number of patients experienced
318 gastrointestinal 110/2599 (4.2%) and sensory 70/2622 (2.7%) problems since discharge.

319

320 A small number of the LS categories were co-existent: 174 (6.6%) participants reported LS
321 from three different categories at the time of the follow-up interview; 88 (3.3%) reported four
322 categories, and 37 (1.4%) reported five categories or more. Co-existence of five most common
323 categories of long-standing symptoms at the time of the follow-up interview is presented in
324 the **Figure S1**.

325

326 Risk factors for all categories were assessed. In multivariable regression analysis, female sex
327 was a predictor of chronic fatigue with an odds ratio of 1.67 (95% confidence interval 1.39 to
328 2.02), neurological (2.03, 1.60 to 2.58), mood and behaviour (1.83, 1.41 to 2.40),
329 dermatological (3.26, 2.36 to 4.57), gastrointestinal (2.50, 1.64 to 3.89), sensory (1.73, 2.06
330 to 2.89) and respiratory (1.31, 1.06 to 1.62) long-standing symptom categories, respectively.
331 The effect of female sex remained unchanged in the sensitivity analyses, which included
332 patients with RT-PCR-confirmed COVID-19 only, for all categories except respiratory and
333 sensory. Pre-existing asthma was consistently associated with neurological (1.95, 1.25 to
334 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18) (**Figures 3 and 4**), with
335 associations remaining significant in the sensitivity analyses. Chronic pulmonary disease was
336 associated with chronic fatigue (1.68, 1.21 to 2.32) (**Figure 5**) and gastrointestinal (1.93, 1.02
337 to 3.43) long-standing symptom categories development. However, an association with
338 gastrointestinal symptoms was not confirmed in the sensitivity analysis. Rheumatological
339 disorder was associated with the mood and behavioural long-standing symptoms (1.97, 1.12-
340 3.33), but the effect was not confirmed in the sensitivity analysis. Confirmed RT-PCR during
341 acute phase was significantly associated with chronic fatigue, neurological, mood and
342 behaviour and gastrointestinal categories, confirming importance of the sensitivity analyses.
343 More details of primary and sensitivity analyses are presented in **Table 2** and forest plots
344 are available as **supplementary material**.

345 Dyspnoea of different severity was reported by 318 (12%) patients during follow-up with 194
346 (7.3%) equivalent to grade 3, 93 (3.5%) grade 4 and 31 (1.2%) grade 5 according to MRC
347 Dyspnoea Scale (**Table S3**).

348

349 Participants reported lower scores (poorer health state) on the EuroQol visual analog scale at
350 follow-up compared with pre-COVID-19 onset, median 80 (IQR, 65-90) vs 85 (70-95)
351 ($p < 0.001$). Significant worsening of the health state compared with pre-COVID 19 was found
352 across all symptom categories, with the highest median difference reported by patients with
353 gastrointestinal (-15), mood and behaviour (-13) and neurological (-10.5) symptoms
354 ($p < 0.001$ for all) (**Table S4**). No statistically significant reduction in health state was found
355 among patients reporting no symptoms. Participants falling into all symptom categories had
356 significantly lower health state than those with no symptoms ($p < 0.001$ for all).


357

Long-standing symptom Category (n [†])	Risk factor	Primary analysis OR (95%CI)	Sensitivity analysis OR (95%CI)	Consistently associated factors*
Chronic fatigue (n = 658)	Female Sex	1.67 (1.39-2.02)	1.81 (1.40-2.34)	Female Sex
	Chronic pulmonary disease	1.68 (1.21-2.32)	1.66 (2.08-2.54)	Chronic pulmonary disease
	Hypertension	1.27 (1.02-1.57)	1.27 (0.94-1.72)	
	RT-PCR “+”	1.23 (1.02-1.47)	NA	
Respiratory (n = 451)	Female Sex	1.31 (1.06-1.62)	1.21 (0.90-1.62)	No
Neurological (n = 375)	Female Sex	2.03 (1.60-2.58)	2.21 (1.54-2.93)	Female Sex
	Asthma	1.95 (1.25-2.98)	2.18 (1.24-3.73)	Asthma
	RT-PCR “+”	1.30 (1.04-1.63)	NA	
Mood and behaviour (n = 284)	Female Sex	1.83 (1.41-2.40)	1.73 (1.22-2.47)	Female Sex
	Asthma	2.02 (1.24-3.18)	2.39 (1.31-4.20)	Asthma
	Rheumatological disorder	1.97 (1.12-3.33)	1.62 (0.69-3.45)	
	RT-PCR “+”	1.45 (1.12-1.87)	NA	
Gastrointestinal (n = 206)	Female Sex	2.50 (1.64-3.89)	2.78 (1.61-4.96)	Female Sex
	Chronic pulmonary disease	1.93 (1.02-3.43)	1.36 (0.54-2.99)	
	RT-PCR “+”	1.56 (1.05-2.33)	NA	
Dermatological (n = 110)	Female Sex	3.26 (2.36-4.57)	3.08 (1.99-4.88)	Female Sex
Sensory (n = 70)	Female Sex	1.73 (2.06-2.89)	1.54 (0.78-3.07)	No

Table 2. Risk factors significantly associated with the different categories of long-standing symptoms in the primary (age, sex, comorbidities, severity and RT-PCR were included


as potential risk factors) and sensitivity (performed in a subgroup of RT-PCR positive patients only) multivariable regression analyses. *- The assessment of robustness is based on the magnitude, direction and/or statistical significance of the estimates. †- Number of patients with at least one long-standing symptom from this category) Statistically significant associations are presented in bold. Abbreviations: OR, Odds Ratio; CI, Confidence interval; NA, Not applicable; RT-PCR “+”, Real-time polymerase chain reaction confirmed SARS-CoV-2 infection.

A



358

B



359

360


361

362

363


Figure 3. Multivariable logistic regression model. Odds ratios and 95% CIs for “Neurological” category of long-standing symptoms at the time of follow-up. Abbreviation: CI, confidence interval. (a) primary analysis (age, sex, comorbidities, severity and RT-PCR were included as potential risk factors); (b) sensitivity analysis (performed in a subgroup of RT-PCR positive patients only).

A



364

B



365

366


367

368

369


Figure 4. Multivariable logistic regression model. Odds ratios and 95% CIs for “Mood and behaviour” category of long-standing symptoms at the time of follow-up. Abbreviation: CI, confidence interval. (a) primary analysis (age, sex, comorbidities, severity and RT-PCR were included as potential risk factors); (b) sensitivity analysis (performed in a subgroup of RT-PCR positive patients only).

A



371

B



372

373

374

375

376

Figure 5. Multivariable logistic regression model. Odds ratios and 95% CIs for “Chronic fatigue” category of long-standing symptoms at the time of follow-up. Abbreviation: CI, confidence interval. (a) primary analysis (age, sex, comorbidities, severity and RT-PCR were included as potential risk factors); (b) sensitivity analysis (performed in a subgroup of RT-PCR positive patients only)

377 **DISCUSSION**

378 To our knowledge, this is the prospective cohort study with the largest sample size and the
379 longest follow-up duration, assessing the long-term health and psycho-social consequences
380 of COVID-19 in hospitalised adults. The cohort included a similar number of RT-PCR-
381 confirmed COVID-19 and those who were clinically diagnosed with COVID-19. We found
382 that six of ten patients experienced at least one symptom of any duration 6 to 8 months after
383 hospital discharge and almost a half of the patients reported at least one LS, with chronic
384 fatigue and respiratory problems being the most frequent LS categories. One in ten patients
385 reported multisystem impacts with three or more categories of long-standing symptoms
386 present at follow-up. LS were experienced by males and females, with a higher risk amongst
387 women, with chronic pulmonary disease associated with chronic fatigue, and asthma with a
388 higher risk of neurological symptoms and mood and behaviour problems.

389

390 The majority of patients experienced LS from the time of discharge, with a smaller number
391 developing symptoms months following discharge. Persistent fatigue and breathlessness
392 were the most frequent LS in our cohort, which is consistent with recent report from China ⁶.
393 Forgetfulness and vision problems were also among the most common, while problems
394 sleeping was less common (10.2%) compared to rates reported by the recent follow-up data
395 from China (26%) ⁶.

396

397 A novel findings relates to the development of symptoms weeks or months since recovery
398 from COVID-19. To our knowledge, this aspect has not been investigated in previous studies,
399 as most of the cohorts did not collect data on the duration of the symptoms present at follow-
400 up. Patterns of the symptom development following COVID-19 should be further
401 investigated in future research.

402

403 Female sex was significantly associated with an increased risk of LS, regardless of symptom
404 category, reflecting previous findings ⁶ and digital App ¹⁶ studies. Chronic pulmonary disease
405 was a risk factor for the development of chronic fatigue. An association between chronic
406 pulmonary disease and severe acute COVID-19 was found in many studies ¹⁷, but it has not
407 been previously reported as a risk factor for COVID-19 sequelae. The presence of chronic
408 pulmonary disease has been previously associated with chronic fatigue syndrome ¹⁸. The
409 pandemic also had a significant adverse impact on care and support for patients with chronic
410 pulmonary conditions, including a reduction in face-to-face clinic availability, lack of access
411 to pulmonary rehabilitation sessions and hospital care during an exacerbation due to fear of
412 COVID-19 exposure ¹⁹. The causality cannot be determined and we are unable to conclude if
413 lack of follow-up and involvement in rehabilitation programmes for chronic pulmonary

414 conditions was the cause of ongoing symptoms. Future research should investigate COVID-
415 19 consequences in this group of patients in greater detail.

416

417 Data from the COVID Symptom Study app in the UK suggested that asthma may be a risk
418 factor for LS related to COVID-19¹⁶. We also found that asthma was associated with an
419 increased risk of LS during follow-up, specifically neurological and mood and behaviour.
420 Although asthma has not been associated with a higher risk of hospital admission and/or in-
421 hospital mortality in COVID-19 patients,^{20,21} different results may be found when
422 considering the long-term consequences of infection. Recent research suggested that COVID-
423 19 sequelae may be associated with the mast cell activation syndrome²² and the Th-2 biased
424 immunological response in asthmatic patients may be responsible for an increased risk of
425 long-term implications of the infection. This finding may point to immune mediated
426 mechanisms but requires confirmation in a larger sample size with a more detailed
427 investigation, including in-clinic visits.

428

429 It is worth noting that in contrast to the Chinese cohort⁶, we did not find significant
430 associations between COVID-19 severity and long-term symptom development. This may be,
431 however, related to the difference in the methodology applied and the small number of
432 severe patients in our cohort. There is a need for further investigation of the frequency with
433 which mild infection are followed by long-term symptoms, mandating a study of non-
434 hospitalised infected subjects.

435

436 Patients with all categories of LS reported significantly lower health state when compared
437 with symptom-free patients. They also considered the health state to be lower than before
438 the COVID-19 episode. This is consistent with previous reports from different countries^{5,6,23}.
439 This finding points to the multi-factorial adverse effects of COVID-19 and to the need for
440 wide ranging and longer term supports.

441

442 A major strength of this study is use of pre-positioned data collection method using ISARIC
443 Core CRF for acute phase data and ISARIC Long-term Follow-up Study CRF. Another
444 strength is the large sample size, as this cohort is the largest follow-up assessment of
445 hospitalised adults to date. Stratification to determine if the symptoms were persistent
446 following COVID-19 was another novel aspect of the study. At the same time, this cohort
447 study has some limitations. First, the study population only included patients within
448 Moscow, although regional clustering is common to all major cohort studies published
449 during the COVID-19 pandemic. Second, acute data were collected from the electronic
450 medical records with no access to additional information that could be potentially retrieved

451 from the medical notes. Third, almost half of the patients in our cohort did not have RT-PCR
452 confirmed COVID-19 infection, although our previous work ³ showed that clinical features of
453 COVID-19 and in-hospital mortality were the same in COVID-19 clinically diagnosed and
454 laboratory-confirmed cases. We also performed sensitivity analyses using data from the
455 laboratory-confirmed COVID-19 patients only to ensure consistency and robustness of the
456 findings. Fifth, some patients may have developed additional comorbidities or complications
457 since the hospital discharge, which were not appropriately captured and could potentially
458 affect the QoL and symptom prevalence and persistence. There is also a risk of recall bias in
459 reporting quality of life and dyspnoea preceding COVID-19.

460

461 At 6-8 months follow-up, many patients experienced symptoms from the time of hospital
462 discharge, with chronic fatigue and respiratory problems being the most common sequelae.
463 Most patients reported symptoms at 6-8 months from the time of discharge, although a
464 subgroup reported symptoms limited to a few weeks and/or months after the acute phase.
465 One in ten individuals had multi-system involvement at the time of the follow-up. Female
466 sex was the main risk factor for most of the long-lasting symptom categories development,
467 while chronic pulmonary disease was associated with a higher risk of chronic fatigue
468 development and asthma with the neurological and mood and behaviour changes. Future
469 studies should focus on patients with multisystem involvement and longer follow-up of a
470 large sample will allow for a better understanding of COVID-19 sequelae and help with the
471 phenotype recognition. Investigation of immunological aspects of the association between
472 asthma and several long-covid outcomes may identify mechanisms and therapeutic targets
473 for therapy to mitigate adverse consequences.

474

475 **Acknowledgments**

476 We thank RFBR, grant 20-04-60063 for supporting the work. We would also like to thank
477 UK Embassy in Moscow for providing a grant supporting our project. We are very grateful to
478 the Sechenov University Hospital Network clinical staff and to the patients, carers and
479 families for their kindness and understanding during these difficult times of COVID-19
480 pandemic. We would like to express our very great appreciation to ISARIC Global COVID-19
481 follow-up working group for the survey development. We would like to thank Mr Maksim
482 Kholopov for providing technical support in data collection and database administration. We
483 are very thankful to Eat & Talk, Luch, Black Market and Academia for providing us the work
484 space in time of need. We are grateful to Ms Asmik Avagyan, Ms Daria Belykh, Ms Ekaterina
485 Belyakova, Ms Anna Berbenyuk, Mr Dmitry Eliseev, Ms Mariia Grosheva, Ms Nelli
486 Khusainova, Ms Maria Kislova, Ms Valeria Klishina, Ms Karina Kovygina, Ms Natalia Kogut,
487 Ms Yana Kohanovskaya, Ms Anastasia Kuznetsova, Ms Elza Lidzhieva, Ms Nadezhda

488 Markina, Mr Georgiy Novoselov, Ms Anna Pushkareva, Ms Olga Romanova, Ms Maria
489 Shoshorina, Ms Jasmin Sibkhan, Ms Olga Spasskaya, Ms Anna Surkova, Ms Nailya
490 Urmantaeva, Ms Ekaterina Varlamova, Ms Margarita Yegiyanyan, Ms Margarita Zaikina, Ms
491 Anastasia Zorina, Ms Elena Zuikova for assistance in data extraction, document translation
492 and help during the project. Finally, we would like to extend our gratitude to the Global
493 ISARIC team and ISARIC Coordinating Centre for their continuous support, expertise and
494 for the development of the outbreak ready standardised protocols for the data collection.

495 REFERENCES

496

- 497 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
498 real time. *Lancet Infect Dis* 2020; **20**(5): 533-4.
- 499 2. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in
500 hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective
501 observational cohort study. *BMJ* 2020; **369**: m1985.
- 502 3. Munblit D, Nekliudov NA, Bugaeva P, et al. StopCOVID cohort: An observational
503 study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city
504 for suspected COVID-19 infection. *Clin Infect Dis* 2020.
- 505 4. Pritchard MG. COVID-19 symptoms at hospital admission vary with age and sex:
506 ISARIC multinational study. *medRxiv* 2020: 2020.10.26.20219519.
- 507 5. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in
508 Patients After Acute COVID-19. *JAMA* 2020; **324**(6): 603-5.
- 509 6. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients
510 discharged from hospital: a cohort study. *Lancet* 2021; **397**(10270): 220-32.
- 511 7. Michelen M, Manoharan L, Elkheir N, et al. Characterising long-term covid-19: a
512 rapid living systematic review. *medRxiv* 2020: 2020.12.08.20246025.
- 513 8. Wise J. Long covid: WHO calls on countries to offer patients more rehabilitation. *BMJ*
514 2021; **372**: n405.
- 515 9. Meeting the challenge of long COVID. *Nat Med* 2020; **26**(12): 1803.
- 516 10. The L. Facing up to long COVID. *The Lancet* 2020; **396**(10266): 1861.
- 517 11. National Institute for Health and Care Excellence (NICE) tSIGNSatRCoGPR. COVID-
518 19 rapid guideline: managing the long-term effects of COVID-19. 2020.
519 <https://www.nice.org.uk/guidance/ng188> (accessed 15-th of January 2021).
- 520 12. Consortium. ISARIC. COVID-19 CORE CASE REPORT FORM ACUTE
521 RESPIRATORY INFECTION CLINICAL CHARACTERISATION DATA TOOL. 2020.
522 [https://isaric.org/wp-](https://isaric.org/wp-content/uploads/2020/10/ISARIC_WHO_nCoV_CORE_CRF_25.08.2020.pdf)
523 [content/uploads/2020/10/ISARIC_WHO_nCoV_CORE_CRF_25.08.2020.pdf](https://isaric.org/wp-content/uploads/2020/10/ISARIC_WHO_nCoV_CORE_CRF_25.08.2020.pdf) (accessed 6-th
524 of February 2021).
- 525 13. The World Health Organization. Global COVID-19 Clinical Platform Case Report
526 Form (CRF) for Post COVID condition (Post COVID-19 CRF). 2021.
527 [https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-](https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-(crf)-for-post-covid-conditions-(post-covid-19-crf-))
528 [\(crf\)-for-post-covid-conditions-\(post-covid-19-crf-\)](https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-(crf)-for-post-covid-conditions-(post-covid-19-crf-)) (accessed 10-th of February 2021).
- 529 14. Davis HE, Assaf GS, McCorkell L, et al. Characterizing Long COVID in an
530 International Cohort: 7 Months of Symptoms and Their Impact. *medRxiv* 2020:
531 2020.12.24.20248802.
- 532 15. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute
533 covid-19 in primary care. *BMJ* 2020; **370**: m3026.

- 534 16. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of Long-COVID:
535 analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App.
536 *medRxiv* 2020: 2020.10.19.20214494.
- 537 17. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the
538 severity of COVID-19: A systemic review and meta-analysis. *J Med Virol* 2020; **92**(10): 1915-
539 21.
- 540 18. Baghai-Ravary R, Quint JK, Goldring JJ, Hurst JR, Donaldson GC, Wedzicha JA.
541 Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease.
542 *Respir Med* 2009; **103**(2): 216-23.
- 543 19. Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. *Eur Respir J* 2020;
544 **56**(2).
- 545 20. Avdeev S, Moiseev S, Brovko M, et al. Low prevalence of bronchial asthma and
546 chronic obstructive lung disease among intensive care unit patients with COVID-19. *Allergy*
547 2020.
- 548 21. Ferastraoaru D, Hudes G, Jerschow E, et al. Eosinophilia in Asthma Patients Is
549 Protective Against Severe COVID-19 Illness. *J Allergy Clin Immunol Pract* 2021.
- 550 22. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-
551 19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis* 2020; **100**: 327-32.
- 552 23. Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with
553 COVID-19 and implications for follow-up: results from a prospective UK cohort. *Thorax* 2020.
554